Comparing [ <sup>18</sup>F]FDG-positron emission tomography and breast magnetic resonance imaging to predict pathological complete response and 3-year invasive disease-free survival in HER2-positive early breast cancer patients: an unplanned exploratory analysis of the PHERGain trial.

Auteurs

García-Mosquera JJ, Pérez-García JM, Ruiz-Borrego M, Stradella A, Bermejo B, Escrivá-de-Romaní S, Calvo Martínez L, Gebhart G, Kerrou K, Gion M, Antonarelli G, Santasusagna Canal S, Rodríguez-Morato J, Mina L, Sampayo-Cordero M, Llombart-Cussac A, Cortés J

  • Date de publication

    November 2025

  • Type

    Article

  • Review

    ESMO Open

  • Researcher's name

    GEBHART GERALDINE

  • Hôpital

    Institut Jules Bordet

  • Service

    Médecine nucléaire IJB

  • PMID

    41202503

  • DOI

    10.1016/j.esmoop.2025.105875